Comparing long-term toxicity and efficacy of combined modality treatment including extended- or involved-field radiotherapy in early-stage Hodgkin's lymphoma.
about
Hodgkin lymphoma, version 2.2015.An individual patient-data comparison of combined modality therapy and ABVD alone for patients with limited-stage Hodgkin lymphoma.Radiotherapy-induced malignancies: review of clinical features, pathobiology, and evolving approaches for mitigating riskBalancing risks and benefits of therapy for patients with favorable-risk limited-stage Hodgkin lymphoma: the role of doxorubicin, bleomycin, vinblastine, and dacarbazine chemotherapy alone.The GHSG Approach to Treating Hodgkin's Lymphoma.Impact of centralized diagnostic review on quality of initial staging in Hodgkin lymphoma: experience of the German Hodgkin Study Group.Current and future immunotherapeutic approaches in Hodgkin lymphoma.Optimisation of chemotherapy and radiotherapy for untreated Hodgkin lymphoma patients with respect to second malignant neoplasms, overall and progression-free survival: individual participant data analysis.Analyses of patterns-of-failure and prognostic factors according to radiation fields in early-stage Hodgkin lymphoma.Radiation-Induced Malignancies Making Radiotherapy a "Two-Edged Sword": A Review of Literature.Radiation-Induced Malignancies: Our Experiences With Five CasesStromal Expression of MARCKS Protein in Ovarian Carcinomas Has Unfavorable Prognostic Value.
P2860
Q30769157-1320C10E-C1FC-4D7D-A243-399A95BC0AABQ35016354-4A1DC5D5-8372-41F8-900B-CDF6CA60B097Q36736612-03E2CE6E-A59C-4E5B-AC3E-E28CEF0B054CQ37383554-E7B0ADFD-B2BC-42CA-9996-4BE9B636CA39Q38506223-65519924-A11C-490B-A6D5-2A2FE73B1FACQ38574490-3862AEEC-FBE0-4151-BB4D-262BDDA0B833Q38848990-70BBDF37-691D-4348-BACC-7A9A7532553BQ40044179-ECF61F6A-90E5-4CAB-A7A7-24F560D622D9Q40694674-63464024-01CE-434E-9CE2-7E8133FDD75DQ41835022-11D4DCA0-B7C2-41F0-A0B2-C87E388EE21FQ42286740-F034E458-E9E0-4D45-AD55-A001DD498A24Q47181311-53752F51-E8F5-43F4-A64D-5C75BFB4FAE1
P2860
Comparing long-term toxicity and efficacy of combined modality treatment including extended- or involved-field radiotherapy in early-stage Hodgkin's lymphoma.
description
2012 nî lūn-bûn
@nan
2012 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Comparing long-term toxicity a ...... arly-stage Hodgkin's lymphoma.
@ast
Comparing long-term toxicity a ...... arly-stage Hodgkin's lymphoma.
@en
Comparing long-term toxicity a ...... arly-stage Hodgkin's lymphoma.
@nl
type
label
Comparing long-term toxicity a ...... arly-stage Hodgkin's lymphoma.
@ast
Comparing long-term toxicity a ...... arly-stage Hodgkin's lymphoma.
@en
Comparing long-term toxicity a ...... arly-stage Hodgkin's lymphoma.
@nl
prefLabel
Comparing long-term toxicity a ...... arly-stage Hodgkin's lymphoma.
@ast
Comparing long-term toxicity a ...... arly-stage Hodgkin's lymphoma.
@en
Comparing long-term toxicity a ...... arly-stage Hodgkin's lymphoma.
@nl
P2093
P2860
P356
P1433
P1476
Comparing long-term toxicity a ...... arly-stage Hodgkin's lymphoma.
@en
P2093
A Heyden-Honerkamp
German Hodgkin Study Group (GHSG)
P2860
P304
P356
10.1093/ANNONC/MDS110
P577
2012-07-05T00:00:00Z